Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $8.2000 (4.99%) ($7.7700 - $8.2000) on Wed. Dec. 4, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.76% (three month average) | RSI | 56 | Latest Price | $8.2000(4.99%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 1.7% a day on average for past five trading days. | Weekly Trend | TGTX advances 0.3% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(65%) ARKG(59%) IBB(58%) ARKK(57%) IWO(56%) | Factors Impacting TGTX price | TGTX will decline at least -1.88% in a week (0% probabilities). VIXM(-40%) VXX(-38%) UUP(-7%) TLT(-7%) IGOV(-1%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -1.88% (StdDev 3.76%) | Hourly BBV | 0 () | Intraday Trend | 4.2% | | | |
|
5 Day Moving Average | $7.97(2.89%) | 10 Day Moving Average | $7.83(4.73%) | 20 Day Moving Average | $7.85(4.46%) | To recent high | 0% | To recent low | 60.8% | Market Cap | $1.039b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |